Evidence map›Paper›PMID 26284300›Full record

ArticleNature communications2015

Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting.

Munitta Muthana, Aneurin J Kennerley, Russell Hughes, Ester Fagnano, Jay Richardson, Melanie Paul, Craig Murdoch, Fiona Wright, Christopher Payne, Mark F Lythgoe and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 161 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Munitta MuthanaDepartments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK.
Aneurin J KennerleyDepartment of Psychology, University of Sheffield, Sheffield S102RX, UK.
Russell HughesDepartment of Oncology, University of Sheffield, Sheffield S102RX, UK.
Ester FagnanoDepartments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK.
Jay RichardsonDepartments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK.
Melanie PaulDepartments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK.
Craig MurdochUnit of Oral &Maxillofacial Medicine &Surgery, University of Sheffield, Sheffield S102RX, UK.
Fiona WrightDepartments of Infection and Immunity, University of Sheffield, Sheffield S102RX, UK.
Christopher PayneCentre for Advanced Biomedical Imaging, Division of Medicine, University College London, London WC1E 6DD, UK.
Mark F LythgoeCentre for Advanced Biomedical Imaging, Division of Medicine, University College London, London WC1E 6DD, UK.
Neil FarrowInstitute for Science and Technology in Medicine, Keele University, Stoke-on-Trent ST4 7QB, UK.
Jon DobsonDepartment of Biomedical Engineering, University of Florida, Gainesville, Florida 32611, USA.
Joe ConnerVirttu Biologics, Glasgow, Glasgow City G51 4TF, UK.
Jim M WildCardiovascular Sciences, University of Sheffield, Sheffield S102RX, UK.
Claire LewisDepartment of Oncology, University of Sheffield, Sheffield S102RX, UK.
University of Sheffield · GBUniversity College London · GBKeele University · GBUniversity of Florida · USVirttu Biologics (United Kingdom) · GB

Funding

British Heart Foundation SP/14/6/31350Cancer Research UK 13028Cancer Research UK C11712/A13028Department of Health NIHR-RP-R3-12-027Medical Research Council G0902317Medical Research Council G0902317/1Medical Research Council MR/J013110/1Medical Research Council MR/K026739/1Medical Research Council MR/M008894/1
6 · The paper itself

Abstract

Cell-based therapy exploits modified human cells to treat diseases but its targeted application in specific tissues, particularly those lying deep in the body where direct injection is not possible, has been problematic. Here we use a magnetic resonance imaging (MRI) system to direct macrophages carrying an oncolytic virus, Seprehvir, into primary and metastatic tumour sites in mice. To achieve this, we magnetically label macrophages with super-paramagnetic iron oxide nanoparticles and apply pulsed magnetic field gradients in the direction of the tumour sites. Magnetic resonance targeting guides macrophages from the bloodstream into tumours, resulting in increased tumour macrophage infiltration and reduction in tumour burden and metastasis. Our study indicates that clinical MRI scanners can not only track the location of magnetically labelled cells but also have the potential to steer them into one or more target tissues.

Indexed as

AnimalsCapillary PermeabilityCell- and Tissue-Based TherapyCells, CulturedContrast MediaFerric CompoundsGadolinium DTPAHumansMacrophagesMagnetic Resonance SpectroscopyMaleMetal NanoparticlesMiceNeoplasms, ExperimentalOncolytic VirusesProstatic NeoplasmsContrast MediaFerric Compoundsferric oxideGadolinium DTPA

Identifiers

PMID26284300
PMCPMC4568295
OpenAlexW2216693079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.